The Lymphocyte Culture Core (LCC), a hybridoma facility, is a research support facility of the University of Virginia School of Medicine and the Cancer Center. The primary function of the LCC is to make available to researchers the most current technology and expertise for the construction and selection of lymphocytemyeloma hybridomas for the production of monoclonal antibodies. The LCC also provides expertise in the use of these reagents in basic research programs. Services are customized to the specific requirements of individual investigators to optimize the recovery of appropriate antigen specific monoclonal antibodies. Initial discussions are held with the investigator and his staff in order to understand the experimental system employed in the laboratory and to determine the specific applications for which monoclonal antibodies are required. The staff of the LCC then plans and executes all aspects of hybridoma construction and selection and monoclonal antibody production. Specifically, the LCC provides approved animal experimentation protocols for all aspects of monoclonal antibody production, including: immunizations, sera collection, intrasplenic injection and ascites production. Center staff immunize animals, collect sera, perform all cell culture aspects of hybridoma construction and selection, and develop ELISA assay strategies appropriate for sera titration and for screening large numbers of hybridoma culture supernatants. Once an appropriate assay system has been developed and used to demonstrate the successful immunization of the necessary animals, fusions are scheduled on a first come first served basis. The center conducts all aspects of cell fusion, assaying by ELISA for specific antibody positive cultures, culturing, cloning, freezing, and recovery of specific antibody producing clones. Investigators receive, upon request, hybridoma culture supernatants and individual hybridoma clones. The center also provides cryopreservation, storage and recovery of cryopreserved cells. Adjunct services include monoclonal antibody isotyping and sub-isotyping, bulk monoclonal antibody production in vitro using disposable bioreactors, ascites production, monoclonal and polyclonal antibody purification by affinity chromatography on recombinant Protein G columns, and antibody inventory, storage and shipping. The LCC also serves as a repository, production facility and distribution point for intellectual property (hybridomas and monoclonal antibodies) licensed by the University of Virginia Patent Foundation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-17
Application #
7726752
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-02-01
Budget End
2008-01-31
Support Year
17
Fiscal Year
2007
Total Cost
$38,597
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Borten, Michael A; Bajikar, Sameer S; Sasaki, Nobuo et al. (2018) Automated brightfield morphometry of 3D organoid populations by OrganoSeg. Sci Rep 8:5319
Olson, Kristine C; Kulling Larkin, Paige M; Signorelli, Rossana et al. (2018) Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes. Cytokine 111:551-562
Pfister, Katherine; Pipka, Justyna L; Chiang, Colby et al. (2018) Identification of Drivers of Aneuploidy in Breast Tumors. Cell Rep 23:2758-2769
Carhart, Miev Y; Schminkey, Donna L; Mitchell, Emma M et al. (2018) Barriers and Facilitators to Improving Virginia's HPV Vaccination Rate: A Stakeholder Analysis With Implications for Pediatric Nurses. J Pediatr Nurs 42:1-8
Hao, Yi; Bjerke, Glen A; Pietrzak, Karolina et al. (2018) TGF? signaling limits lineage plasticity in prostate cancer. PLoS Genet 14:e1007409
Obeid, Joseph M; Kunk, Paul R; Zaydfudim, Victor M et al. (2018) Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time? Cancer Immunol Immunother 67:161-174
Wallrabe, Horst; Svindrych, Zdenek; Alam, Shagufta R et al. (2018) Segmented cell analyses to measure redox states of autofluorescent NAD(P)H, FAD & Trp in cancer cells by FLIM. Sci Rep 8:79
Olmez, Inan; Love, Shawn; Xiao, Aizhen et al. (2018) Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro Oncol 20:192-202
Wang, T Tiffany; Yang, Jun; Zhang, Yong et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective ?-chain cytokines, decreases leukemic T-cell viability. Leukemia :
Yao, Nengliang; Zhu, Xi; Dow, Alan et al. (2018) An exploratory study of networks constructed using access data from an electronic health record. J Interprof Care :1-8

Showing the most recent 10 out of 539 publications